MG
LEGN icon

Michael Gelband’s Legend Biotech LEGN Stock Holding History

Michael Gelband’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,202
Closed -$1.33M – 1798
2024
Q3 		$1.33M Buy
+27,202
New +$1.45M 0.01% 884
2022
Q4 		– Sell
-93,744
Closed -$3.83M – 1902
2022
Q3 		$3.83M Buy
+93,744
New +$4.4M 0.05% 501
2021
Q4 		– Sell
-33,932
Closed -$1.72M – 2407
2021
Q3 		$1.72M Buy
33,932
+16,632
+96% +$692K 0.02% 788
2021
Q2 		$710K Buy
+17,300
New +$588K 0.01% 1177
2020
Q4 		– Sell
-7,478
Closed -$231K – 2189
2020
Q3 		$231K Sell
7,478
-32,973
-82% -$1.11M ﹤0.01% 1414
2020
Q2 		$1.72M Buy
+40,451
New +$1.58M 0.04% 489

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Michael Gelband's LEGN Position: Q4 2024 in Review

Michael Gelband sold out of Legend Biotech (LEGN) in Q4 2024, closing a stake of 27,202 shares — an estimated $1.33M sold.

Michael Gelband first reported a position in LEGN in Q2 2020 and held it in 6 quarters. The position peaked at $3.83M in Q3 2022. 211 funds tracked by Wall St. Rank hold LEGN as of Q4 2024.

  • Michael Gelband reported no remaining Legend Biotech position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 27,202 Legend Biotech shares in Q4 2024, an estimated $1.33M.
  • Michael Gelband first reported a position in Legend Biotech in Q2 2020 and held it in 6 quarters.
  • Michael Gelband's Legend Biotech position peaked at $3.83M in Q3 2022.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.